IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression

Sujan K Dhar\textsuperscript{a}, Vishnupriyan K\textsuperscript{b}, Sharat Damodar\textsuperscript{c}, Shashi Gujar\textsuperscript{d} and Manjula Das\textsuperscript{b}\textsuperscript{*}

\textsuperscript{a} Beyond Antibody, InCite Lab, MSMF, 8\textsuperscript{th} Floor MSMC, Bommasandra, Bangalore, India
\textsuperscript{b} Tumor Immunology, MSMF, 8\textsuperscript{th} Floor MSMC, Bommasandra, Bangalore, India
\textsuperscript{c} Department of Hematology, 7\textsuperscript{th} Floor MSMC, Bommasandra, Bangalore, India
\textsuperscript{d} Room, 11J, 5850 College Street, Sir Charles Tupper Medical Building, Dalhousie University, Halifax, Nova Scotia, Canada B3H 1X5

\textsuperscript{*Corresponding author:}
Dr Manjula Das (manjula msmf@gmail.com)
Tumour Immunology, Mazumdar Shaw Medical Foundation
8\textsuperscript{th} Floor MSMC, Bommasandra, Bangalore, India
Email: manjula msmf@gmail.com

Keywords: COVID-19, Meta-Analysis, Cytokines, Logistic Models

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Aims: SARS-CoV-2, an infectious agent behind the ongoing COVID-19 pandemic, induces high levels of cytokines such as IL-1, IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ etc in infected individuals which contribute towards the underlying disease pathophysiology. Nonetheless, exact association and contribution of every cytokine towards COVID-19 pathology remains poorly understood. Delineation of the role of the cytokines during COVID-19 holds the key of efficient patient management in clinics. This study performed a comprehensive meta-analysis to establish association between induced cytokines and COVID-19 disease severity to help in prognosis and clinical care.

Main methods: Scientific literature was searched to identify 13 cytokines (IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-17, TNF-α and IFN-γ) from 18 clinical studies. Standardized mean difference (SMD) for selected 6 cytokines IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ between severe and non-severe COVID-19 patient groups were summarized using random effects model. A classifier was built using logistic regression model with cytokines having significant SMD as covariates.

Key findings: Out of 13 cytokines, IL-6 and IL-10 showed statistically significant SMD across the studies synthesized. Classifier with mean values of both IL-6 and IL-10 as covariates performed well with accuracy of ~ 92% that was significantly higher than accuracy reported in literature with IL-6 and IL-10 as individual covariates.

Significance: Simple panel proposed by us with only two cytokine markers can be used as predictors for fast diagnosis of patients with higher risk of COVID-19 disease deterioration and thus can be managed well for a favourable prognosis.
Introduction

COVID-19 pandemic caused by SARS-CoV-2 has emerged as a major threat to mankind affecting 18+ million people resulting in over 700,000 deaths (1) worldwide. Exuberant inflammation manifested as elevated levels of cytokines, commonly referred as “cytokine storm” (CS) often leads to critical conditions like ARDS (acute respiratory distress syndrome) and death due to multi-organ failure(2).

Innate immune response is the first step of defense mechanism against viral infection. Pattern recognition receptors in host dendritic cells recognize viral genomic DNA or RNA to initiate production of cytokines and chemokines(3) which in turn recruit immune cells like macrophages, neutrophils and T-cells to the site of infection based on their source and target cells(4). Pro-inflammatory cytokines including type I/II interferons, IL-1, IL-6 and TNF-α play major role in initial response, whereas anti-inflammatory molecules like IL-10 are produced during sustained infection to keep a check on inflammation and maintain immune homeostasis(5). Heightened CS induced acute lung damage leading to fatality(6) is a signature of coronavirus family reported earlier for MERS-CoV and SARS-CoV infections(7,8).

In COVID-19, elevated levels of both pro-inflammatory and anti-inflammatory cytokines are reported in multiple clinical studies (9–11). A recently published extensive meta-analysis summarized elevated levels of IL-2, IL-2R, IL-4, IL-6, IL-8, IL-10, TNF-α and IFN-γ in severe group of patients, whereas no significant increase was found in the levels of IL-1β and IL-17(12). A two-arm meta-analysis study synthesized from individual patient data reported statistically significant odds ratio (p < 0.05) to sever disease for only two cytokines - IL-6 and IL-10(13). Some meta-analysis efforts reported difference in IL-6 level between severe and non-severe COVID-19 patients in terms of Standardized Mean Difference (SMD) (14), mean difference (15) or ratio of means (16) values that can potentially be used as cut-off to discriminate between severe and non-severe patients. All these meta-analysis summary results were associated with high level of heterogeneity (I² ~ 98 – 100%). Another synthesis over three clinical studies determined the elevated ratio IL-6/IFN-γ in severe patients (17) with substantial heterogeneity (I² = 79%).

Clinical studies with COVID-19 patient cohorts explored the role of IL-6 alone (18) or along with other cytokines including IL-10, IL-2, IL-4, TNF-α and IFN-γ as prognosticator...
for severe disease(19). Meta-analysis studies described before(12,14–16,20,21) concluded elevated levels of cytokines in severe COVID-19 patients but did not attempt to establish their prognostic significance, except the study by Elshazli et al who performed decision tree and ROC curve analysis to assess prognostic potential of multiple laboratory parameters including IL-6(13). However, despite numerous clinical studies and meta-analyses any reliable prognostic method that can predict the progression of a patient to severe form of disease based on on-admission cytokine levels remains elusive. In this study, we attempt to arrive at a prognostic method through meta-analysis of the levels of commonly used 13 cytokine markers between severe and non-severe patient groups by building a classifier using a logistic regression model.

**Methods**

**Literature Search**

We performed the meta-analysis following PRISMA guidelines(22). Literature search was performed in Pubmed, Google Scholar and in preprint archives such as medRxiv, bioRxiv and SSRN library for articles in English published in year 2020 till 31 May 2020. Search terms included COVID-19-specific terms in title of article ("2019-nCov" OR "nCoV-2019" OR "novel coronavirus" OR "SARS-CoV-2" OR "COVID-19" OR COVID19 OR "novel coronavirus") along with terms such as “cytokine level” and combinations of common cytokine names and gene symbols. Search strategy was reviewed by all authors and it was decided to retain non-peer reviewed articles in selection in view of the present emerging situation. Identified articles were screened and shortlisted to clinical studies with inclusion criteria as only clinical studies with laboratory data for at least two cytokines for severe and non-severe COVID-19 patient groups. Exclusion criteria for shortlisting included review articles, opinions and commentaries, studies that include other pathological conditions or complications associated with COVID-19 and studies without mean (SD) or median (IQR) data of cytokines for each group.

**Data Extraction**

Selected articles were reviewed independently by two authors (VK and SKD). Data was extracted from articles using standardized forms and was cross-validated. Cytokine levels reported as median (IQR) was converted to mean (SD) using standard methods(23). One study reported non-severe patient data across two groups(24) which
were combined using recommendations in Cochrane Handbook (25) section 6.5.2.10. Another study represented data in subgroups of IgG levels and Neutrophil-to-Lymphocyte ratio (NLR) (26), for which we retained data from only the IgG-low subgroups as that would be closest to early stage of infections, and combined subgroups of high and low NLR values.

**Meta-Analysis and Meta-Regression**

To assess the effect of each marker, we used the standardized mean difference (SMD) of measured cytokine level (in pg/mL) between severe and non-severe groups including Hedges’ correction for positive bias. All calculations were carried out using the metafor library (27) on R statistical software platform. Meta-regression of SMD of a marker was carried out using mixed-effects model with differences in age and sex (measured as percentage of male patients). Publication bias in the studies was analyzed using Funnel Plot and Egger’s regression test. Sensitivity of meta-analysis results was assessed by repeating the analysis with leaving out one study at a time and observing significant changes in heterogeneity and summary effect.

**Classifier Development**

We built a classifier using logistic regression model for categorization of patient groups in to severe and non-severe categories based on mean values of cytokines in the groups. Classifier performance using individual cytokine values or combination of multiple cytokine values are assessed from the Receiver Operating Characteristics (ROC) curve analysis and the area under the curve (AUC).

**Results**

**Study Details**

The search yielded a total of 99 “hits” which were screened to select 18 articles containing cytokine levels of severe and non-severe patients reported from clinical studies (Fig. 1). All 18 selected studies were conducted in China and included 1,242 non-severe and 915 severe COVID-19 patients (Table 1). Out of the 18 studies, 7 were non-peer reviewed studies (24, 26, 28–32) published online in preprint archives.
**Table 1: Details of selected studies**

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Non-severe patients</th>
<th>Severe Patients</th>
<th>Clinical Definitions of Severe Patients</th>
<th>Cytokines Measured</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>Age</td>
<td>Male %</td>
<td>n</td>
</tr>
<tr>
<td>Chen, 2020(33)</td>
<td>10</td>
<td>50.3 (10.1)</td>
<td>70.0</td>
<td>11</td>
</tr>
<tr>
<td>Feng, 2020(28)</td>
<td>94</td>
<td>62.9 (13.7)</td>
<td>61.7</td>
<td>20</td>
</tr>
<tr>
<td>He, 2020(34)</td>
<td>12</td>
<td>42.3 (16.8)</td>
<td>31.1</td>
<td>16</td>
</tr>
<tr>
<td>Lv, 2020(35)</td>
<td>115</td>
<td>54.3 (41.5)</td>
<td>50.4</td>
<td>155</td>
</tr>
<tr>
<td>Nie, 2020(24)</td>
<td>72</td>
<td>40.3 (19.3)</td>
<td>29.1</td>
<td>25</td>
</tr>
<tr>
<td>Qin, 2020(36)</td>
<td>166</td>
<td>52.1 (15.4)</td>
<td>48.2</td>
<td>286</td>
</tr>
<tr>
<td>Shi, 2020(29)</td>
<td>22</td>
<td>49.7 (12)</td>
<td>59.7</td>
<td>21</td>
</tr>
<tr>
<td>Song, 2020(30)</td>
<td>31</td>
<td>48 (16.5)</td>
<td>51.6</td>
<td>42</td>
</tr>
<tr>
<td>Wan, 2020(37)</td>
<td>102</td>
<td>43.1 (13.1)</td>
<td>53.9</td>
<td>21</td>
</tr>
<tr>
<td>Wang, 2020(38)</td>
<td>55</td>
<td>40 (14.1)</td>
<td>45.0</td>
<td>14</td>
</tr>
<tr>
<td>Wei, Su, 2020(39)</td>
<td>131</td>
<td>60.1 (12.4)</td>
<td>45.0</td>
<td>98</td>
</tr>
<tr>
<td>Xu, 2020(40)</td>
<td>80</td>
<td>55.7 (17)</td>
<td>37.5</td>
<td>45</td>
</tr>
<tr>
<td>Zhang, Zhou, 2020(26)</td>
<td>44</td>
<td>53.5 (20.1)</td>
<td>47.7</td>
<td>21</td>
</tr>
<tr>
<td>Zhang, Wang, 2020(31)</td>
<td>29</td>
<td>44.3 (15.8)</td>
<td>58.6</td>
<td>14</td>
</tr>
</tbody>
</table>
## Table 1: Clinical Definitions of Severe Patients and Cytokines Measured

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Non-severe patients</th>
<th>Severe Patients</th>
<th>Clinical Definitions of Severe Patients</th>
<th>Cytokines Measured</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhang, Yu, 2020(41)</td>
<td>93</td>
<td>38.2 (12.2)</td>
<td>18</td>
<td>63.3 (24.9)</td>
</tr>
<tr>
<td>Zhao, 2020(32)</td>
<td>53</td>
<td>44.8 (15.9)</td>
<td>18</td>
<td>63.9 (17.2)</td>
</tr>
<tr>
<td>Zheng, 2020(42)</td>
<td>22</td>
<td>46.9 (14.7)</td>
<td>74</td>
<td>56.8 (13.7)</td>
</tr>
<tr>
<td>Zhu, 2020(43)</td>
<td>111</td>
<td>50 (15.5)</td>
<td>57.5 (11.7)</td>
<td>NHC guideline, pulmonary lesion</td>
</tr>
</tbody>
</table>

NHC guideline: (a) Respiratory distress, RR≥30/min, (b) Oxygen saturation level (SpO₂) ≤ 93% at rest and (c) Arterial blood oxygen partial pressure (PaO₂) / oxygen concentration (FiO₂) ≤ 300 mm Hg.

Pulmonary lesion: > 50% lesion progression within 24-48h in pulmonary imaging

WHO guideline: Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO₂ < 90% on room air

Age in mean (SD)

---

**Figure 1: Workflow for selection of studies**

[Flowchart showing the selection process]
In most studies the severe patient group was designated based on National Health Commission of China guidelines (44) that specifies (a) Respiratory distress, RR≥30/min, (b) Oxygen saturation level (SpO$_2$) ≤ 93% at rest and (c) Arterial blood oxygen partial pressure (PaO$_2$)/oxygen concentration (FiO$_2$) ≤ 300 mm Hg. For some studies, pulmonary lesion progression > 50% within 24-48 hours on imaging was used as additional criteria. One study used WHO guideline (45) that categorizes severe patients as adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO$_2$ < 90% on room air.

Weighted mean of age of patients in severe group (59.7y, range 55.9 – 69.8) was higher than the non-severe group (50.2y, range 38.2 – 62.9). Severe group also had larger percentage of male patients (57.8%, range 35.7 – 90.9) than non-severe group (48.4%, range 29.1 – 70.0).

Measurement of total 13 cytokines (IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-17, TNF-α and IFN-γ) were reported in the selected 18 studies. However, 13 studies were considered for further analysis since they reported analysis of five or more studies in at least 1000 patients (Supplementary Table S1). These studies reported levels of only 6 cytokines (IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ).

**Meta-analysis of Cytokine Levels**

Meta-analysis for SMD value of each marker using a random-effects model showed moderate and statistically significant elevation in severe patients for two cytokines viz. IL-6 (SMD 0.53, 95% CI: 0.26 - 0.80, p < 0.001) (Fig. 2a) and IL-10 (SMD 0.64, 95% CI: 0.38 – 0.91, p < 0.0001) (Fig. 2b). Level of IFN-γ, the type II interferon, showed a weak elevation in severe group (SMD 0.11, 95% CI: -0.01 – 0.23, p = 0.078) with moderate significance. Summary effect size of other markers IL-2 (p = 0.281), IL-4 (p = 0.305) and TNF-α (p = 0.258) were not significant (Table 2).
**Figure 2:** Standardized mean difference of (a) IL-6 and (b) IL-10 between severe and non-severe COVID-19 patients
Table 2: Meta-analysis result summary of six cytokines

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Random Effect Model SMD (95% CI)</th>
<th>Summary Effect p.value</th>
<th>Heterogeneity (I²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-2</td>
<td>0.12 (-0.10, 0.35)</td>
<td>0.281</td>
<td>66.9%</td>
</tr>
<tr>
<td>IL-4</td>
<td>0.15 (-0.13, 0.42)</td>
<td>0.305</td>
<td>79.2%</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.53 (0.26, 0.80)</td>
<td>0.0001</td>
<td>72.0%</td>
</tr>
<tr>
<td>IL-10</td>
<td>0.65 (0.38, 0.91)</td>
<td>&lt;0.0001</td>
<td>73.0%</td>
</tr>
<tr>
<td>TNF-α</td>
<td>0.10 (-0.08, 0.28)</td>
<td>0.258</td>
<td>50.8%</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>0.11 (-0.01, 0.23)</td>
<td>0.078</td>
<td>0%</td>
</tr>
</tbody>
</table>

**Meta-Regression with Age and Gender Difference**

Summary effects of both IL-6 and IL-10 showed substantial heterogeneity (I² ~ 72-73%) source of which was explored by carrying out meta-regression of IL-6 and IL-10 using (i) SMD of patient age and (ii) difference in male percentage between severe and non-severe groups as moderators in a mixed-effects model. Results revealed IL-10 levels having a dependence on the age difference (coefficient 0.63, p = 0.012), whereas the dependence of IL-6 on age was not significant (p > 0.05, Fig. 3). No dependence of IL-6 and IL-10 levels were found on gender expressed as difference of male percentage between the two groups (Supplementary Fig. S1). Above results ascribe some of the observed heterogeneity in IL-6 and IL-10 SMD to difference in average age between severe and non-severe group.
Our results indicate that out of the analysed cytokines, levels of only the pro-inflammatory IL-6 and the immuno-suppressive IL-10 are significantly elevated in the severe group of patients, an observation reported in other studies as well (19,46). This prompted us to assess the prognostic potential of these markers by developing a logistic regression model using IL-6 and IL-10 mean values as covariates to classify the patient groups as severe and non-severe across all 18 studies. Model using both IL-6 and IL-10 as covariates showed an overall accuracy of 91.7% and area under the corresponding ROC curve as 0.957 (95% CI: 0.898 – 1), which is higher than the corresponding values using IL-6 (accuracy 77.8%, AUC 0.821) and IL-10 (accuracy 80.6%, AUC 0.878) individually as covariates (Table 3, Fig. 4). Model using both IL-6 and IL-10 showed nearly 100% specificity and 83.3% sensitivity for classification in severe and non-severe categories.
Table 3: Classifier performance summary using only IL-6, only IL-10 and both IL-6 and IL-10 as input variables

<table>
<thead>
<tr>
<th>Classifier</th>
<th>Accuracy (%)</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>AUC (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6</td>
<td>77.8</td>
<td>66.7</td>
<td>88.9</td>
<td>0.821 (0.680, 0.962)</td>
</tr>
<tr>
<td>IL-10</td>
<td>80.6</td>
<td>61.1</td>
<td>100</td>
<td>0.878 (0.766, 0.990)</td>
</tr>
<tr>
<td>Both IL-6 and IL-10</td>
<td>91.7</td>
<td>83.3</td>
<td>100</td>
<td>0.957 (0.898, 1)</td>
</tr>
</tbody>
</table>

Figure 4: ROC curve for classifier performance using only IL-6, only IL-10 and both IL-6 and IL-10 as input parameters

Publication Bias and Sensitivity

Publication bias towards higher SMD of IL-10 levels reported in smaller-size studies manifested as asymmetry in Funnel plot and Egger’s regression test ($p < 0.001$), whereas the corresponding bias was not significant ($p = 0.151$) for IL-6 (Supplementary Fig. S2). Sensitivity analysis of the studies showed a large reduction of heterogeneity in IL-6 ($I^2$ value from 72% to 25%) and a moderate reduction for IL-10 (73% to 55%) by leaving out one particular study from the analysis (Supplementary Fig. S3).
Limitations

Primary limitation of this meta-analysis is that the studies are restricted only to Chinese ethnicity, which was not by design but due to the fact that most initial studies were reported from this geographic region, the site of first spread. Also 7 of the 18 studies were non-peer reviewed publications selected as per search strategy. There was some heterogeneity in clinical criteria for severe disease as shown in Table 1. Also recruitment of patients in the studies were at different stages of disease progression, which might have caused bias in the on-admission measurement of laboratory parameters in cytokines.

Discussion

With the sustained spread of COVID-19 in most societies, a suitable prognostic test that can predict progression of a patient to severe state of disease with reasonable accuracy is need of the hour for efficient management and care. Cytokine storm caused by a dysregulation of immune system through increase in immune cell activation versus suppression of anti-inflammatory response is likely to hold the key in discovery of such prognostic factors.

Elevated levels of IL-6, a pro-inflammatory molecule, is known to down-modulate NK cell activity and are also found to be associated with reduction in granzyme and perforin levels causing impairment of lytic activities(47). In COVID-19 patients exacerbation symptoms such as increased body temperature, elevation in inflammation markers like CRP and serum ferritin and progressed chest computed tomography images were associated with increased IL-6 levels which showed a downturn during recovery(48). This association of IL-6 with pulmonary conditions were reported earlier in patients with pneumonia(49) or severe pneumonitis caused by radiation therapy(50).

IL-10, on the other hand, is an anti-inflammatory cytokine that was found elevated in severe COVID-19 patients(2,33,36). Levels of IL-6, IL-10 and TNF-α were also found to be indicators of T-cell exhaustion in COVID-19 patients(51). IL-10 is a multifunctional cytokine whose primary function is to limit the inflammatory response. However, IL-10 is also known to introduce anergy or non-responsiveness of T-cells in anti-tumour cell response(52) as well as in viral infection(53). Blockade of IL-10 using antibody against
IL-10 or its receptor or genetic removal of IL-10 resulted in elimination of infection by virus (53–55) or bacterial pathogen (56).

Though the levels of cytokines are increased in severe COVID-19 patients, its implication in a therapeutic perspective remains unclear. Corticosteroids that can potentially suppress cytokines by inhibiting NF-κB transcription factor have been used on COVID-19 patients. However, a meta-analysis across studies involving infection of SARS-CoV, SARS-CoV-2 and MERS-CoV showed increased mortality risk ratio (RR 2.11, 95% CI: 1.13–3.94) for patients treated with corticosteroids (57). In an unique study, anti-TNF-α antibody drug, infliximab, was administered to a small group (n = 7) of severe COVID-19 patients without any pre-existing auto-immune condition (58). Though the patients showed decrease in IL-6 level and increase in lymphocyte count post-administration, the cohort size was not adequate to make any conclusion on the end-point benefits. Few other studies used etanercept (59), adalimumab (60) and infliximab (61) therapy successfully for COVID-19 patients, but with pre-existing auto-immune conditions. On the other hand, there have been several studies targeting IL-6 levels using siltuximab, an IL-6 inhibitor or tocilizumab, an IL-6 receptor inhibitor in severe COVID-19 patients. A recent review (62) on few such studies did not reveal any conclusive benefits due to lack of appropriate control groups in design or inadequate statistical significance. Further, the timing for anti-IL-6 agent administration remains critical since an early administration may negatively affect the innate response, while the late administration may not yield desired benefits. Some of the ongoing clinical results using anti-IL-6 therapy will shed more light in near future.

Therapeutic strategy of targeting IL-10 has been a nascent topic for infective diseases. Mice models treated with the immunomodulator compound Ammonium trichloro(dioxyethylene-O-O’)tellurate (AS101) that inhibits IL-10 transcription showed an improvement in survival from sepsis-related death (63). Similarly, lymphocytic choriomeningitis virus (LCMV) infected mice when treated with anti-IL-10 antibody exhibited enhanced T-cell responses resulting in increased IFN-γ production and reduction in viral load (53). Blockade of IL-10 signalling using an antibody that targets IL-10 receptor also reduced viral titre and persistence in LCMV-infected mice (54,55). Similar in vivo experiments with SARS-CoV-2 infected animal models will be needed to establish IL-10 as a therapeutic target for severe and critical COVID-19 disease.
Despite the unclarity on therapeutic potential of IL-6 and IL-10, their observed levels of
elevation in severe COVID-19 patients have prompted clinical researchers to explore use
of them as prognosticators. In an earlier study with pneumonia-affected children, IL-
6/IL-10 ratio on admission was found to be an indicator of severe disease with sensitivity
and specificity of 76.5% and 83.3% respectively (49). In COVID-19 context, ROC curve
analysis on an Italian cohort of 77 patients showed IL-6 as a prognostic factor for
combined end-point of progression to severe disease and/or in-hospital mortality with
AUC = 0.8(18). However, performance of prognosis for progression to severe disease was
poorer with AUC = 0.75. In the recently reported meta-analysis over a large number of
studies, classifier performance was found to be higher for neutrophil count (AUC = 0.831),
lymphocyte (AUC = 0.867) and D-dimer (AUC = 0.876) than using IL-6 as covariate(AUC
= 0.632)(13). Another research with 102 COVID-19 patients used logistic regression to
evaluate potential of multiple cytokines to diagnose severe and critical patients. Results
revealed best prognostic performance for IL-6 (AUC = 0.83), followed by IL-10 (AUC =
0.73) as individual covariates whereas the model with all cytokines showed marginally
better performance (AUC 0.86, sensitivity 80.0%, specificity 75.9%).

Other than these cytokines, D-Dimer, CRP level and NLR are explored as diagnostic or
prognostic markers in COVID-19. Though a couple of studies focused only on their
diagnostic potential for COVID-19 positivity(64,65), ROC analysis in a study with 84
patients hospitalized with COVID-19 pneumonia(66) showed modest performance of
NLR and CRP to predict a 7-day endpoint as AUC values of 0.69 (CRP), 0.76 (NLR) and
0.080 (both). Another study with 93 confirmed patients established a slightly higher
performance with AUC values as 0.84(NLR) and 0.71(CRP) to distinguish severe and non-
severe patients. Pooled ROC curve analysis in a couple of meta-analysis studies showed
modest classifier performance for CRP and D-Dimer with AUC values as 0.84 and 0.69(67)
and 0.88 and 0.77(68) respectively to discriminate severe and non-sever patients. Since
in all these cases the AUC values are below 0.9, predictive values for NLR, CRP and D-
Dimer to diagnose severe patients may remain restricted. A recent proteomics study(69)
predicted excellent classification performance (AUC = 0.96) for severe and non-severe
COVID-19 patients using 22 serum proteins and 7 metabolites as covariates. However, a
proteomics infrastructure is not so common in a clinic, limiting clinical utility of this test.
In this context, results of the meta-analysis and classification obtained in this study assumes importance in multiple aspects. Firstly, synthesis of a large number of studies (more than many of the cited meta-analyses) demonstrates a significant difference in values for only two cytokines – IL-6 and IL-10 with counter-acting mechanisms, reaffirming the dysregulation of immune response in progression to a severe state. Secondly, even at the absence of individual patient data, ROC curve analysis with mean values of IL-6 and IL-10 levels manifests a high level of classifier performance (AUC > 0.9) in distinguishing severe from non-severe group patients, which is higher than classifier performance from individual studies (18,19). Our results are likely to be more robust since variations from multiple patient cohorts are included in this synthesis. And lastly, it opens the possibility of further research to establish a validated diagnostic test using these two markers for management of COVID-19 patients. Since we are working with mean values of markers in severe or non-severe patient groups and not individual patient-level values, we have refrained from using IL-6/IL-10 ratio as the classifier as was done in the pneumonia study (49). However, availability of patient data from multiple cohorts of severe and non-severe patients can firmly establish and validate the test with the ratio or any other transform as the basis of classification.

Conclusion

Our findings, summarized over multiple studies, indicate a possible dysregulation in immune response against COVID-19, characterized by two counter-acting cytokines IL-6 and IL-10, shifts the balance between non-severe to severe category of patients, and hence measurement of both markers is necessary to demarcate the boundary. Measurement of serum levels IL-6 and IL-10 are inexpensive and can be performed on admission to clinics or care centres with minimum facilities. Such measurement will be key to identify patients with a greater likelihood of progression to severe disease and thereby to adopt necessary precautionary measures. Further trials with multiple cohorts of COVID-19 patients or assimilation of patient-level data from existing cohorts will be needed to establish and validate the test. Other than the diagnostic potential, option of possible therapeutic strategy targeting either IL-6 or IL-10 or both is likely to emerge through analysis of such data.
Declaration of Interest

Authors declare that there are no conflicts of interest.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author Contributions

SKD: Conceptualization, Data curation, Formal analysis, Writing - original draft, VK: Data curation, Writing – original draft, SD: Validation, SG: Writing – editing & review, MD: Project administration, Writing – editing & review

Acknowledgement

SKD acknowledges Prof. Joy Kuri, Chair, Department of Electronic Science and Engineering, Indian Institute of Science, Bangalore for providing the computational resources.

Supplementary Material

Enclosed

References


Maris CH, Chappell CP, Jacob J. Interleukin-10 plays an early role in generating virus-specific T cell anergy. BMC Immunol. 2007;8:9–12.


Duret PM, Sebbag E, Mallick A, Gravier S, Spielmann L, Messer L. Recovery from


Characterization of COVID-19 Patient Sera II Article Proteomic and Metabolomic